Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932279 · ClinicalTrials.gov registry record
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
A clinical trial of Cutaneous T Cell Lymphoma, sponsored by Northwestern University.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT03932279 is a study of Cutaneous T Cell Lymphoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 300 participants, above the 55-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (445% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03932279, a study of Cutaneous T Cell Lymphoma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.
Conditions Studied
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2028-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03932279
The ClinicalTrials.gov registry entry for NCT03932279 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 55-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (445% higher). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT03932279 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03932279 about?
NCT03932279 is a clinical study titled "Characterization of the Microbiome in Cutaneous T Cell Lymphoma". Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.
What is the current status of trial NCT03932279?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2019-01-30. Estimated completion is 2028-08-31.
What conditions does trial NCT03932279 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma.
Who is sponsoring clinical trial NCT03932279?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03932279 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.